PLAUR抗体PLAUR一抗抗体urokinase-type
plasminogen activator (uPA) receptor antibody抗体PLAUR Antibody抗体- ￥1100 - 1980
- CUSABIO
- CN
- CSB-PA236241
- 2025年07月14日
- ELISA,WB,IHC;ELISA:1:2000-1:5000,WB:1:500-1:2000,IHC:1:50-1:200
- Rabbit
- Human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Fusion protein of Human PLAUR
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
/
- 标记物：
Non-conjugated
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q03405
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA,WB,IHC;ELISA:1:2000-1:5000,WB:1:500-1:2000,IHC:1:50-1:200
- 浓度：
>95%,Antigen affinity purification
- 靶点：
PLAUR
- 抗体英文名：
PLAUR Antibody
- 抗体名：
urokinase-type plasminogen activator (uPA) receptor antibody
- 规格：
100μl/50μl
| 规格： | 100μl | 产品价格： | ￥1980.0 |
|---|---|---|---|
| 规格： | 50μl | 产品价格： | ￥1100.0 |
保存缓冲液
-20℃, pH7.4 PBS, 0.05% NaN3, 40% Glycerol功能
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验is almost catalytic when compared to antisense silencing. Of these targets, the uPAR-uPA system and MMPs holds great promise. Targeting uPA/uPAR may provide additive or synergistic treatment benefits if used in combination with conventional therapeutics
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene
attachments. One such enzyme, the serine protease urokinase-type plasminogen activator (uPA), converts enzymatically inactive plasminogen into the widely acting protease plasmin, which degrades several extracellular matrix components and also activates
of pericellular proteases; among those, the serine protease, urokinase-type plasminogen activator (uPA), its inhibitor PAI-1, and its cellular receptor uPA-R (CD87). Apart from its proteolytic functions, the uPA system is endowed with properties affecting
技术资料暂无技术资料 索取技术资料
